July 2, 1995European Heart Journal
Current and future perspectives on antithrombotic therapy of acute myocardial infarction
Why the study?
Does the addition of anticoagulation (heparin or hirudin) to aspirin confer a net benefit in patients with suspected acute myocardial infarction?
Population
Patients with suspected acute myocardial infarction
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Antithrombotic choice after AMI remains unresolved; leaves open whether anticoagulation adds net benefit to aspirin pending dedicated trials.
Structured PICO
Does the addition of anticoagulation (heparin or hirudin) to aspirin confer a net benefit in patients with suspected acute myocardial infarction?
P
Population
Patients with suspected acute myocardial infarction
I
Intervention
Antithrombotic therapy (antiplatelet therapy with aspirin alone or addition of anticoagulation with heparin or hirudin)
This perspective outlines the need for ongoing trials to determine the optimal antithrombotic regimen (aspirin alone vs. aspirin plus anticoagulation) for acute myocardial infarction.
Cite This Study
Hennekens et al. (1995) studied this question.